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Abstract
Purpose Various combination treatment
regimens have been tried to improve the
short-term efﬁcacy of intravitreal
monotherapy for the treatment of macular
oedema (MO) secondary to retinal vein
occlusion (RVO). Our study introduces the
RandOL protocol (Ranibizumab and Ozurdex
with Laser photocoagulation) of initial anti-
VEGF therapy, controlling recurrent non-
ischaemic MO with an intravitreal steroid
and applying laser therapy to non-perfused
retina. We describe our 12-month follow-up
experience on timing for adjunctive therapy
and real-world effectiveness and safety
data.
Methods A retrospective analysis was
carried out on 66 consecutive treatment-naive
RVO patients with MO who received our
RandOL treatment regimen. Baseline visual
acuity (VA) and central retinal thickness
(CRT) were compared with 12-month result.
Results At 12 months, 77% had signiﬁcant
VA improvement, 52% had ≥ 3-line
improvement, and 15% were worse.
Signiﬁcant improvements in CRT were
observed in 97% (baseline median
CRT= 531 μm (IQR 435–622) reduced to
245 μm (IQR 221–351, Po0.001) at 12 months);
76% achieved a dry fovea at 1 year. Mean
number of total injections required was 5.5
(range 2–11) and 6% required ≥ 9 injections in
1 year. Although 70% received additional
Ozurdex, 82% received ≥ 1 sessions of laser
therapy. The BRVO subgroup achieved better
VA and CRT improvement at 1 year, but
small numbers limit deﬁnitive statistical
conclusions.
Conclusions Our real-world results using a
combination treatment protocol for RVO-
related MO achieved similar desirable
anatomical and visual outcomes as with a
single-agent therapy with less intravitreal
re-treatment rates at ﬁrst year. Randomised
controlled studies are needed to evaluate the
role of laser and the ideal timing of
combination therapy.
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Introduction
Retinal vein occlusion (RVO) is the second most
common retinal vascular disease after diabetic
retinopathy and is estimated to affect 16 million
adults worldwide, with a reported prevalence of
4.6% in those aged 480 years.1,2 Following the
introduction of intravitreal therapies into routine
clinical practice, the treatment options for macular
oedema (MO) secondary to RVOs have expanded.
The beneﬁts of anti-VEGF therapies (including
Bevacizumab, Ranibizumab, and Aﬂibercept)
and intraocular steroid depot (dexamethasone
implant) are well established and widely used in
the United Kingdom. All agents with the
exception of Bevacizumab are licensed and
approved by NICE (National Institute for Health
and Care Excellence).3–6 Although the results
from pivotal studies using monotherapy are
promising, the need for an average of nine
injections in the ﬁrst year is challenging for
service provision as well as patient compliance
and clinic attendances.5,7,8
As with many published treatment regimens,
our departmental audit results on off-label
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Bevacizumab in treating chronic MO in RVO patients
conﬁrmed the practical dilemma and signiﬁcant variation
in deciding on the optimal loading dose and re-treatment
regimen.9 As the effectiveness of intravitreal
monotherapy appears to be short term, discontinuation
often sees the rebound of MO. Hence, there is a desire to
explore other treatment modalities such as combination
therapy, which may address the multifactorial
pathophysiological aspects of this disease.10,11
Published combination regimens have varied and most
offered the addition of compulsory steroids and limited
guidance on management pathway.12,13 We introduced a
clinical treatment pathway for combination therapy for
RVO-related MO: the RandOL protocol (Ranibizumab
and Ozurdex with Laser photocoagulation) aiming to
standardize and optimize our local RVO treatment
strategy. This protocol proposes an initial anti-VEGF
regimen, followed by an optional intravitreal steroid
and/or laser therapy. We hoped to potentially achieve the
same desirable anatomical and visual outcomes as with
single-agent therapy but with less intravitreal re-
treatment rates. In this paper, we describe our 12-month
follow-up experience on timing for adjunctive therapy
and real-world effectiveness and safety data.
Methods
This paper reports the audited results on all consecutive
new RVO patients who attended the RVO clinic
implementing the new RandOL protocol treatment
regimen between November 2013 to April 2014 at one
hospital (Birmingham and Midland Eye Centre).
Retrospective data collection included demographics,
past medical and ocular histories, and adverse effects.
Our primary outcomes were changes in visual acuity
(VA) and central retinal thickness (CRT) after the initial
loading dose of anti-VEGF and at 1 year, when compared
with baseline. Other recorded data included the
frequency of injections and interval of adjunctive
therapies over a follow-up period of 12 months. Standard
clinical care and informed consent were obtained from all
patients but given this was a service development plan
review using a new local treatment protocol for our
department, no ethical approval was required, as
conﬁrmed by our local Research Governance authority.
Standard ‘Good Clinical Practice’ applied to all patients
when obtaining consent for investigations and
procedures. A preliminary audit was also performed on
the ﬁrst 40 patients to assess the effectiveness and safety
of the protocol, and results were presented and discussed
in our local clinical governance meeting. Our 12-month
real-world results are based on the ﬁrst 66 consecutive
treatment-naive RVO patients with established MO.
Clinical evaluation and intravitreal procedure
All RVO referrals were ﬁrst assessed in a dedicated RVO
diagnosis clinic and subsequently managed in the RVO
review clinic. Clinical evaluation at every clinic visit
included Snellen chart visual acuity (VA) measurement,
slit-lamp biomicroscopy, Goldmann tonometry for
intraocular pressure (IOP) measurement, and central
retinal thickness (CRT) as quantitative measurement of
MO using spectral-domain optical coherence tomography
(3D-OCT 2000, Topcon, Tokyo, Japan). Wide-ﬁeld fundus
ﬂuorescein angiogram (FFA), using wide-ﬁeld
Optos200Tx scanning laser Ophthalmoscope (Optos PLC,
Dunfemline, UK), was also performed at baseline and
repeated when clinically indicated.
All patients were re-assessed at 4 weeks following any
intravitreal injection to assess VA, CRT, and IOP.
Subsequently, stable patients (resolved MO) were
reviewed at an interval of 6 weeks (if they received an
anti-VEGF) or 3 months (if they received a steroid).
Intravitreal injections were performed using aseptic
technique and topical Chloramphenicol 0.5% was used
after the procedure for 1 week.
RandOL protocol
The RandOL protocol is a combination therapy regimen
of initial anti-VEGF therapy, focussing on eliminating
residual retinal ischaemia by means of laser therapy and
controlling recurrent non-ischaemic MO using an
intravitreal steroid. At the start of our new patient
management pathway in November 2013, the NICE-
approved intravitreal agents available for the treatment of
RVO-related MO were Ranibizumab (Lucentis 0.5 mg in
0.05 ml, Novartis, Basel, Switzerland) and dexamethasone
implant (Ozurdex 0.7 mg, Allergan, Irvine, CA, USA).
Figure 1 is the RandOL protocol ﬂow chart, which depicts
an initial loading dose of three intravitreal Ranibizumab
injections at 4 weekly intervals. Additional Ranibizumab
would be indicated for those with an insufﬁcient response
or recurrence of MO in the evidence of persistent
ischaemia. Dexamethasone implant is indicated for
recurrent MO only in the non-ischaemic retina (as
established by wide-ﬁeld FFA) at any timescale.
Generally, dexamethasone implant was to be avoided in
glaucoma patients with preexisting extensive visual ﬁeld
loss secondary to advanced glaucomatous optic disc
cupping and patients with refractory intra-ocular
pressure control.
Laser intervention
The RandOL protocol advised application of
angiography-guided laser therapy on areas of non-
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perfused retina only: 360° pan-retinal photocoagulation
(PRP) for CRVO; sector PRP and/or macular grid laser
(omitting central fovea zone) for HRVO and BRVO. Laser
treatment was decided at ﬁrst clinic review after the
completion of Ranibizumab loading phase and repeated
at different visits if FFA conﬁrmed residual ischaemia. All
laser photocoagulation was performed by different laser
operators (clinicians) applying laser-machine-speciﬁc
laser settings, using conventional Argon laser machine or
pattern scanning laser (Valon TT Multispot Lasers, Valon
Lasers, Finland), which are available in the department
during the intervention period.
Data analyses
Descriptive statistics were used to show demographics
and baseline characteristics.
Snellen fractions were converted to non-continous
logMAR (logarithm of the minimum angle of resolution)
units by a standard conversion method for statistical
purposes.14,15 Changes in both VA and CRT at various
time points from baseline were tested for statistical
signiﬁcance using Wilcoxon signed-rank test. Statistical
analyses were performed using Microsoft Excel 2016 for
Windows and a P-value of o0.05 was considered as
statistically signiﬁcant.
Results
Demographics and baseline characteristics
There were 98 treatment-naïve RVO patients attended in
the study window period of 6 months, with 12-month
follow-up data available for only 90 patients as 8 patients
had incomplete data (6 patients were transferred back to
continue their eye-care elsewhere; 2 patients were
deceased prior to ﬁrst intravitreal treatment). From this
No MORecurrence  MO  
RandOL Flow Chart 
First diagnostic clinic: 
VA/ IOP/ OCT/ wide-field FFA 
BP/ blood test 
Injection loading phase: 
Ranibizumab x3 (4 weekly)  
First clinic after loading phase:  
4 weeks post last injection (VA/ IOP/ OCT +/- FFA) 
Add Ranibizumab if ischaemia, 
Add Ozurdex if no ischaemia 
(Laser applied to non-perfused 
retina, at any stage after post-
loading phase) 
Review clinic:  
6 weekly initially, extend 
by 2 weeks for next visit 
if stable longer 
Recurrence with MO  
RVO with MO 
VA=Visual acuity, IOP=Intraocular pressure check, OCT=Optical coherence 
tomography, FFA= Fundus fluorescein angiography, BP=Blood pressure.  
Ozurdex= dexamethasone implant 
Guidance for intravitreal agent choice in recurrence MO: 
Ranibizumab is to be continued in the presence of clinical or angiographic retinal 
ischaemia (macular or peripheral). The number of re-injections is dependent on the 
scale of recurrence MO (e.g 1 to 3 injections, 4 weekly) decided by treating clinician. 
Dexamethasone implant (Ozurdex) is the choice in the absence of retinal ischaemia 
(confirmed by FFA, independent of any laser application), and is repeatable after 4-
month as decided by treating clinician
Figure 1 RandOL protocol ﬂow chart for treating retinal vein
occlusions (RVO) with macular oedema (MO).
Table 1 Demographic and baseline characteristics
Total RVO, n= 66 CRVO, n= 29 HRVO, n= 9 BRVO, n= 28
Mean age, years (SD; range) 72 (12, 47–94) 77 (10, 53–92) 70 (11, 49–79) 67 (12, 47–94)
Gender
Male 32 (48%) 15 4 12
Female 34 (52%) 14 5 16
Race
Caucasian 47 (71%) 23 5 19
Asian 12 (18%) 4 0 8
Black 7 (11%) 2 4 1
Presenting ocular features and history
Other eye old RVO 6 (9%) 1 0 5
Same eye recurrence 6 (9%) 4 0 2
Known glaucoma 14 (21%) 8 3 3
Newly diagnosed OHT 17 (26%) 7 4 6
Rubeotic glaucoma 3 (5%) 3 0 0
Abbreviations: BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; HRVO, hemi- retinal vein occlusion; OHT, ocular hypertension;
RVO, retinal vein occlusion.
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cohort, only 63 patients presenting with initial MO and 3
patients developed MO at a later stage; the primary end-
point results (VA and CRT analyses) are therefore based
on data from the total of 66 patients who received the
RandOL regimen.
Table 1 describes baseline demographics of the 66
patients with unilateral eye involvement: 29 had CRVO,
28 of BRVO, and 9 of HRVO. Despite a high non-
Caucasian population in our hospital catchment area, we
observed a higher RVO presentation from Caucasians.
Table 1 shows that 5% of our cohort RVOs presented with
severe ocular ischaemic complications of rubeotic
glaucoma, and 18% had history of previous RVO with 9%
recurrence in the same eye (untreated) of ≥ 6-month
duration. In our series, 21% have glaucoma and 26% are
newly diagnosed glaucoma or ocular hypertension at
RVO presentation.
Treatment exposure
The majority of the treated patients (85%) received their
ﬁrst intravitreal injection in ≤ 14 days from ﬁrst diagnostic
clinic. Patients who received RandOL regimen achieved a
mean total of 5.5 of all intravitreal injections in 12 months
(Figures 2a and b). Only 4 patients (6%) needed ≥ 9 total
injections, and 50 (76%) needed ≤ 6 injections (Figure 2b).
The mean number of Ranibizumab injections was 4.3
(range 2–11, one patient missed the third loading dose
owing to travelling abroad), and the mean number of
dexamethasone implant injections was 1 (range 0–2). Of
the 66 patients receiving the RandOL regimen, 46 (70%)
were suitable and received additional dexamethasone
implant. The timing of introducing the ﬁrst
dexamethasone implant was on average 2.6 months (SD
0.9, range 1–5 months) after the completion of the initial
Ranibizumab loading phase.
A high number of patients (54/66, 82%) received one or
more sessions of laser therapy at any stage during the
12-month review (Figure 2a table). Subgroup analyses
showed that majority received 1–2 laser sessions
(Figure 2c) but frequency of laser sessions would depend
on variables (laser machine and operator) and wide-ﬁeld
ﬂuorescein angiogram depiction on laser adequacy. The
three patients who presented with rubeotic glaucoma
with ischaemic retina received ≥ 9 injections of only
Ranibizumab plus extensive laser PRP of 4–5 sessions and
required additional cyclodiode laser therapy to control
the IOP.
Visual outcomes and subgroup analyses
Table 2 shows baseline median VA in LogMAR units was
0.71 (Snellen 6/30), which improved to 0.48 (Snellen 6/18)
at postloading review, which was maintained at the
month 12 visit (Po0.001). At 1 year, 77% of patients had
vision improvement, 52% improved by at least three lines.
The number of patients achieving 6/12 vision or better
was 45.5% (30/66) at 1 year, a signiﬁcant increase
compared with baseline of 19.7% (13/66 patients). Similar
results were obtained when the analysis was performed
separately for each RVO subgroup except for the CRVO
Frequency of combination therapy over 12 months 
Total RVO 
n=66 
CRVO  
n=29 
HRVO 
n=9 
BRVO  
n=28 
Total injections 
Mean frequency (SD) 
Mode (range) 
5.5 (1.8) 
5 (2-11) 
5.9 (2.0) 
5 (2-11) 
5.2 (1.5) 
7 (3-7) 
5 (1.6) 
4 (3-9) 
Ranibizumab only 
Mean frequency (SD) 
Mode (range) 
4.3 (1.8) 
3 (2-11) 
4.7 (2.1) 
3 (2-11) 
4.3 (1.3) 
6 (3-6) 
4.0 (1.5) 
3 (3-8) 
Ozurdex only 
Mean frequency (SD) 
Mode (range) 
1.1 (0.8) 
1 (0-2) 
1.1 (0.9) 
2 (0-2) 
0.8 (0.7) 
1 (0-2) 
1.0 (0.8) 
1 (0-2) 
Laser Procedures 54 (82%) 24 (83%) 7 (78%) 23 (82%) 
RVO=Retinal vein occlusion, CRVO=Central retinal vein occlusion, HRVO=Hemi 
retinal vein occlusion, BRVO=Branch retinal vein occlusion, SD=Standard deviation 
Ozurdex= dexamethasone implant 
Number of total injections received in RVO cohort in 12 months 
Number of laser sessions received by RVO subgroups in 12 
months 
0
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Figure 2 Treatment exposure over 12 months. (a) Frequency of
combination therapy over 12 months. (b) Number of total
injections received in the RVO cohort in 12 months. (c) Number
of laser sessions received by RVO subgroups in 12 months.
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group, where the visual result at 1 year was of borderline
statistical signiﬁcance (P= 0.055).
Anatomical outcomes and subgroup analyses
Table 2 shows the baseline median CRT was 531 μm. The
median reductions in CRT from baseline at the
postloading visit and at month 12 were statistically
signiﬁcant (Po0.001): 64 patients(97%) had improved
CMO at 1 year, 76% had anatomical achievement of dry
fovea (no foveal cyst in OCT depiction).
Subgroup analysis shows a lower presenting CRT of
499 μm in BRVO compared with CRVO, and HRVO had a
closer CRT presentation to BRVO. All three subgroups
had median CRT reductions at 1 year, which was
statistically signiﬁcant.
Adverse events and associated procedures
There were no cases of endophthalmitis in our series.
Raised intraocular pressures (IOP421 mmHg, or higher
than baseline IOP) were not detected after Ranibizumab
injections but were recorded 4 weeks after
dexamethasone implant injection in 19 of the 46 patients
(41%): 12 of these patients were already on antiglaucoma
eye drops (known and treated ocular hypertension or
glaucoma), 2 of which had only intraocular pressure spike
after second dexamethasone implantation but not after
the ﬁrst. All raised intraocular pressures secondary to
dexamethasone implant were controllable by topical
therapy alone. The other observed adverse effect related
to dexamethasone implant was minor vitreous
haemorrhage in two patients following injection and
resolved with no further complication (Table 3).
There were ﬁve poor controlled glaucoma patients
(likely to be the cause of RVO) in this cohort and received
Ranibizumab injections; they had undergone early
procedures (peripheral iridotomies and selective laser
trabeculoplasty) as part of their glaucoma treatment plan
by their glaucoma specialist. They did not show evidence
of worse IOP spike(s) following intravitreal injections.
Table 2 Comparison of changes in vision and central retinal thickness: baseline vs 1 year and subgroup analyses
Total RVO, n= 66 CRVO, n= 29 HRVO, n= 9 BRVO, n= 28
Comparison of visual acuity (VA) in LogMAR (Snellen equivalent)
Baseline: median VA (IQR) 0.71 (6/30) (0.43–1.16) 1.00 (6/60) (0.52–1.41) 0.72 (6/30) (0.41–1.05) 0.60 (6/24) (0.3–0.78)
aPostloading: median VA (IQR) 0.48 (6/18) (0.18–0.84)
Po0.001
One year: median VA (IQR) 0.48 (6/18) (0.18–0.78) 0.78 (6/36) (0.48–1.14) 0.44 (6/15) (0.15–0.54) 0.54 (6/20) (0.30–0.78)
Po0.001 P= 0.055 P= 0.033 Po0.001
One year of visual changes
Worse 10 (15%) 8 (28%) 1 (11%) 1 (4%)
Stable 5 (8%) 2 (7%) 1 (11%) 3 (11%)
Improved 51 (77%) 19 (66%) 7 (78%) 17 (61%)
Improved by 3 lines 34 (52%) 13 (45%) 4 (44%) 16 (57%)
Achieved 6/12 or better 30 (45.5%)
Comparison of central retinal thickness (CRT) changes in μm
Baseline: median CRT (IQR) 531 (435–622) 571 (466–663) 513 (430–559) 499 (403–553)
aPost loading: median CRT (IQR) 239 (215–290)
Po0.001
One year: median CRT (IQR) 245 (221–351) 236 (208–332) 285 (243–386) 252 (224–347)
Po0.001 Po0.001 P= 0.009 Po0.001
Abbreviations: BRVO, branch retinal vein occlusion; IQR, interquartile-range (statistical analysis using Wilcoxon signed-rank test); CRVO, central retinal
vein occlusion; HRVO, hemi-retinal vein occlusion; RVO, retinal vein occlusion. a Subgroup analyses on VA and CRT were not performed in the
postloading phase.
Table 3 Adverse effects and other ocular procedures in the
cohort
Ozurdex-related complications
Raised intraocular pressure 421 mm Hg 19/46 (41%)
Vitreous haemorrhage 2/46 (4%)
Cataract related to injection procedure 0
Cataract related to Ozurdex Unknown
Cataract operation and other procedures
Cataract surgeries 12/66 (18%)
RVO retinopathy worsened after cataract sugery 6/12 (50%)
Laser iridotomies/trabeculoplasty 5
Cyclodiode laser (for rubeotic glaucoma only) 3
Progression to rubeotic glaucoma 0
Endophthalmitis 0
Abbreviations: Ozurdex, dexamethasone implant; RVO, retinal vein
occlusion.
Total number of RVO patients who received RandOL regimen= 66.
Total number of RandOL patients who received Ozurdex= 46.
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Number of patients needing intraocular surgery over
the 12 months are summarized as follows: 12 patients
underwent cataract surgery (2 combined with goniolysis).
None of the 12 cataracts were secondary to injection
trauma, but there was no clear recording if these were
steroid-related effects. For the ﬁrst six patients who
underwent uneventful phacoemulsiﬁcation, ﬁve had
signiﬁcant worsening of retinal haemorrhages at ﬁrst
postoperative review (Table 3). In the subsequent six
patients who underwent intraocular surgery in the latter
part of the audit period, the surgery was carefully timed
to have (or closely follow) a recent Ranibizumab injection,
and these latter patients were not noted to have
worsening of retinal hemorrhages or recurrence of RVO at
the postoperation visit. Seven patients of this postcataract
surgery group accounted for 13% of the cohort, who
achieved 43 lines VA improvement in 1 year. Cataract
surgery could be safely considered during the ‘active
treatment period’ if the procedure was carefully timed.
Discussion
In this report, we have described our RandOL protocol, a
staged combination treatment regimen for RVO with MO,
which was designed by a group of retinal specialists
through review of the guidelines and evidence-based
literature, and was approved and implemented locally as
part of a service development plan, to facilitate our ‘real-
world’ specialist eye service. Staged combination therapy
using our RandOL protocol achieved the same desirable
anatomical and visual outcomes as with a single-agent
therapy with less intravitreal re-treatment rates at 1 year.
Speciﬁcally, using a mean of 4.3 Ranibizumab injections
and one dexamethasone implant over 12 months, we
achieved a median visual improvement of 77% and 52%
had415-letter gain, with 76% achieving a completely dry
fovea at month 12. Although not a direct head-to-head
comparison, these outcomes compare very favourably to
the 12-month ﬁndings from CRUISE study of 77% below
250 μm (8.8 Ranibizumab injections) and BRAVO study of
84% below 250 μm (8.4 Ranibizumab injections). In our
series, the appropriate change in practice on optimal
timing of cataract surgery also eliminated the risk of
worsening RVO in the second part of the re-audit period
when the loop was closed, consistent with our approach
of introducing an interim audit design.
Intravitreal steroids and anti-VEGF therapies are
known to be effective and may have complementary
effects on molecular levels in reducing retinal vascular
permeability.16–19 The combination of Bevacizumab with
dexamethasone implant as treatment for RVO patients
had been more frequently explored, showing equally
favourable results in vision and anatomical improvement,
although studied numbers were small and study follow-
up was short.12,13 The retrospective SHASTA study
compared dexamethasone implant monotherapy vs
combination of dexamethasone implant with anti-
VEGF.20 This found that visual outcomes were similar in
both groups, and as in our series, they showed signiﬁcant
reduction in the required number of injections in the
combination group, whereby the number of anti-VEGF
injections after dexamethasone implant reduced to 2.7
over a 6-month period with combination therapy. They
also reported a high cataract rate of 7.1–19.5%, which is
not unusual with any intravitreal steroid agent. Our series
found a cataract surgery rate of 18%, which was higher
compared with monotherapy of Ranibizumab studies
(CRUISE and BRAVO) of 7% and GENEVA, which
reported a rate of 11 eyes in 163 patients. One explanation
was that our series had not excluded any media opacity at
presentation, which would have been an exclusion
criterion in many prospective trials.
Our study is the ﬁrst report on Ranibizumab, with an
optional dexamethasone implant as treatment paradigm
in a real-world setting. A recent prospective trial based on
mixed anti-VEGF choice with a ﬁxed injection of
dexamethasone implant 2 weeks after anti-VEGF injection
had similar favourable visual and anatomical outcomes
but exposed all patients to steroid-related adverse effect,
resulting in the expected high rate of cataract surgery
(62%).21 The advantage of our protocol regimen is to
individualize patient’s treatment response, optimizing
adjunctive dexamethasone implant only in the ‘suitable’
(ie, non-ischaemic retina) hence minimizing the known
agent-related adverse effects.
Laser therapy for retinal ischaemia
Our laser use (that is, aim and delivering method) was
different from the focal laser used in diabetic
maculopathy whereby the latter was aimed at promoting
MO resolution by targeting leaking microaneurysms.
Indeed, our laser application was purposefully delivered
to non-perfusion retina (identiﬁable by wide-ﬁeld FFA)
aiming to eliminate ischaemia (hence possible retinal
neovascularization) rather than direct effect on inducing
MO resolution. As signiﬁcantly raised intraocular VEGF
levels are detectable in RVO eyes, the rationale of initially
applying an anti-VEGF agent (short-acting) followed by
laser therapy (permanent effect) to theoretically eliminate
retinal ischaemia and to reduce the VEGF level load
formed the basis of our RandOL protocol.16–19
A few randomised controlled trials, such as the CVOS
study and more recent case series, have attempted to
improve MO through eliminating peripheral retina
ischaemia by laser therapy alone or as an adjunctive
therapy.11,22,23 Singer’s case report favours this approach
by reporting a single rubeotic glaucoma patient who
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achieved resolution of co-existing rebound MO following
extensive peripheral laser treatment.11 In the CVOS study,
155 eyes with CRVO receiving laser monotherapy went
on to demonstrate angiographic evidence of reduced MO,
but this was not correlated with improved vision and did
not support the use of laser for MO in CRVO.22
Nevertheless, Spade’s small series of 10 CRVO patients
was possibly the closest to sharing our laser strategy
(peripheral laser on non-perfused retina guided by wide-
ﬁeld angiography).23 The author compared changes in
VA and injection frequency in the 6 months preceding the
once-off laser treatment vs 6 months after and reported no
reduction in Ranibizumab injection frequency nor VA
improvement in that small patient cohort with short
follow-up duration.23 Similar results were found by the
RELATE trial, a larger randomised controlled trial
investigating different dosages of Ranibizumab arms
(allowing rescue laser after month 6) vs Ranibizumab
alone.24 Arguably, other variables that are much difﬁcult
to investigate such as duration of CRVO and the extent of
peripheral ischaemia may have inﬂuence on the
effectiveness and frequency of laser therapy.
Although direct comparisons are not possible with our
cohort, there have been a few large randomised trials
reporting more encouraging results on combined therapy
with initial anti-VEGF injections vs laser alone and
allowing a later regime of combined therapy in BRVO
patients.25,26 For example, the VIBRANT study concluded
substantial VA improvement at week 52 when rescue
treatment was allowed after week 24 (laser added to
Aﬂibercept-arm, aﬂibercept to laser-arm), suggesting a
potential beneﬁt of the combination regimen.25 However,
the BRIGHTER study concluded that Ranibizumab with
or without laser had superior improvement in VA
compared with the laser alone arm at 6 months and
further suggested that VA gain was not affected by retinal
ischaemic status in BRVO.26
The beneﬁts of adjunctive peripheral/macular laser on
non-perfused retina of RVO patients are still debatable.
Although published randomised clinical trials have
concluded that ‘laser to non-perfused retina’ may have no
effect on visual outcome, there are few studies focussed
on establishing the role of laser as a preventative measure
from retinal neovascularizations. From our own
experience in the past few years, there are increasing
numbers of late complications (retinal neovascularization
and vitreous haemorrhage) presented to eye casualty
from untreated RVO or RVO treated with solely anti-
VEGF therapy. This raises a dilemma for clinicians in
deciding if anti-VEGF therapy alone could halt the
progression of late RVO complications or would laser
remain the ultimate answer for long-term prevention?
Randomised controlled trials are therefore needed to
evaluate the role of laser on ischaemic RVO.
Poor visual outcome group
Information on the poor visual outcome group is difﬁcult
to obtain when most studies and clinical trials usually
exclude patients with advanced severity in their clinical
presentation. Although the numbers are small, our
subanalysis identiﬁed that 13 of the 66 RVO patients
(19%) who had poor visual outcome (worse than 6/60) at
12 months, all shared one or more of these three
presenting features: rubeotic glaucoma, established
relative afferent pupillary defect, or initial dense
haemorrhagic RVO. All except one patient in this poor
vision group presented with CRVO. This subgroup was
also older (by a mean of 10 years) compared with the age
characteristics of our cohort overall, with more medical
co-morbidities. The poorer treatment outcome in this
severe disease spectrum is also closely related to the poor
clinic attendance, as disability from systemic medical
problems may prevent patients from receiving the
optimal treatment regimen.
In this series, the protocol successfully reversed the
visual outcome of one of the three established rubeotic
glaucoma patients. Although the range of presenting CRT
measurements in this subgroup was very wide (233–
961 μm), almost half (5/13) had a CRT of 4600 μm.
However, the CRT at presentation may not, at least in
isolation, be as strong a prognostic factor as might
intuitively be expected. Nevertheless, the CRT (at
12 months) of this subgroup majority showed fovea
thinning of o200 μm as a contributory factor to poor
visual outcome.
The main strength of this study is the availability of
prospectively planned and uniformly collected follow-up
data on a consecutive cohort of patients receiving a new
local treatment protocol, thus giving strong
representation of the actual ‘real-world’ experience and
results, especially when it also included the spectrum of
subgroup analyses and disease severity. We also
delivered a pragmatic treatment regimen, easy to
understand and execute by clinicians, including training
grades, hence reducing the variation in management plan
among clinicians. Our study limitations related to its
observational design, without a comparator and the use
of non-parametric visual acuity scores derived by
conversion from Snellen acuities.
In conclusion, our real-world result using a
combination treatment protocol for RVO-related MO
achieved similar desirable anatomical and visual
outcomes as with a single-agent therapy with less
intravitreal re-treatment rates at ﬁrst year. The reduced
number of injections with combination regimen may
translate to signiﬁcant beneﬁts for patients, health-care
providers, and commissioners. Although the protocol
provides a rationale for optional adjunctive therapy based
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on the elimination of ischaemia at different stages of
treatment pathway, the beneﬁts of laser to areas of non-
perfused retina remains debatable in relation to altering
visual outcomes or preventing late complications, such as
retinal neovascularization. Randomised controlled studies
are needed to evaluate these issues and to address the
ideal timing of combination therapy.
Summary
What was known before
K Combination therapy to anti-VEGF with/without steroid
or anti-VEGF with/without laser.
K Small numbers.
K Mostly short-term result.
What this study adds
K A guidance on a pragmatic combination treatment
regimen for RVO CMO (easy to understand and execute
by clinicians, including training grades, reducing the
variation in management plan among clinicians).
K Provides actual real-world experience, including subgroup
analyses/disease severity.
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